These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37559729)

  • 1. Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma.
    Gu HY; Zhao JW; Wang YS; Meng ZN; Zhu XM; Wang FW; Zheng AH; Wu GQ
    Front Immunol; 2023; 14():1148425. PubMed ID: 37559729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.
    Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
    Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
    Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H
    Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
    Neelis KJ; Hartong SC; Egeland T; Thomas GR; Eaton DL; Wagemaker G
    Blood; 1997 Oct; 90(7):2565-73. PubMed ID: 9326222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report.
    Chamseddine S; LaPelusa M; Carter K; Nguyen V; Mohamed YI; Sakr Y; Rojas-Hernandez CM; Hatia RI; Hassan M; Goss JA; Elsayes KM; Rashid A; Sun R; Tran Cao HS; Amin HM; Kaseb AO
    J Gastrointest Oncol; 2024 Jun; 15(3):1324-1330. PubMed ID: 38989410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer.
    Okuzumi S; Kamata H; Emoto K; Shimizu T; Otake S; Irie H; Chubachi S; Ikemura S; Yasuda H; Fukunaga K
    Intern Med; 2023 Jul; 62(14):2113-2121. PubMed ID: 36450461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
    BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of granulocyte colony-stimulating factor in the treatment of pancytopenia secondary to colchicine overdose.
    Katz R; Chuang LC; Sutton JD
    Ann Pharmacother; 1992 Sep; 26(9):1087-8. PubMed ID: 1384817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
    Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
    Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-induced adrenalitis.
    Iqbal I; Khan MAA; Ullah W; Nabwani D
    BMJ Case Rep; 2019 Dec; 12(11):. PubMed ID: 31791986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Pancytopenia Following Single Dose Methotrexate In Psoriasis: A Rare And Potentially Lethal Manifestation.
    Singh A; Choudhary R; Chhabra N; Ganguly S; Rathore V
    Curr Drug Saf; 2021; 16(1):110-113. PubMed ID: 33106147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
    Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
    Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe Therapy-Related Pancytopenia Caused by UFT and LV in a Patient with Ascending Colon Cancer].
    Akiyama T; Yasutomi J; Kusashio K; Matsumoto M; Suzuki T; Iida A; Imamura N; Yoshizumi A; Harano R; Udagawa I; Ohtsuka M
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1399-1401. PubMed ID: 29394647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab.
    Hisamatsu Y; Morinaga R; Watanabe E; Ohtani S; Shirao K
    Am J Case Rep; 2020 Feb; 21():e920809. PubMed ID: 32018275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.